Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic (HOLX) reported an insider transaction by a company director on 10/20/2025. The director exercised 7,402 non-qualified stock options at $36.04 per share (code M) and on the same day sold 7,402 shares at an average price of $73.07 (code S). Following these transactions, the director beneficially owns 47,336 shares, held directly. The activity was carried out under a Rule 10b5-1 trading plan adopted on February 19, 2025. The exercised option was set to expire on March 2, 2026.
Hologic, Inc. agreed to be acquired by affiliates of Blackstone and TPG in an all-cash merger. Each share will be converted into $76.00 in cash plus one non-tradeable contingent value right (CVR) worth up to $3.00 in cash, subject to milestone achievement under a CVR agreement. The Board unanimously approved the deal and will recommend that stockholders adopt the merger agreement. Upon closing, Hologic will become a wholly owned subsidiary and its common stock will be delisted.
Closing requires majority stockholder approval, expiration or termination of HSR waiting periods, specified antitrust and foreign direct investment clearances, no blocking order, and CFIUS review after a 30‑day period from notice. The outside date is July 21, 2026, with limited extensions. Termination fees include $540 million (company), $225 million for certain go‑shop outcomes, and a $900 million parent fee for specified failures. Financing commitments include $9.5B first‑lien term loans, $2.0B second‑lien term loans, a $750M revolver, and use of Hologic’s approximately $2.2B cash as of September 27, 2025. A go‑shop runs through 12:01 a.m. ET on December 5, 2025.
Stephen P. MacMillan, Chairman, President and CEO of Hologic, reported multiple transactions on 09/22/2025 under a Rule 10b5-1 plan adopted December 12, 2024. He exercised 138,358 non-qualified stock options at an exercise price of $39.96 and sold common stock in multiple blocks: 22,240 shares at a weighted average of $66.13, 77,418 shares at $67.04, and 38,700 shares at $67.32. After these transactions he directly beneficially owned 1,234,624 shares and indirectly held 1,146,829 shares through the MacMillan Family Trust. The report notes 1,079,673 restricted/performance stock units deferred under the company Deferred Equity Plan and 346 shares acquired via the employee stock purchase plan since his last Form 4.
HOLOGIC INC (HOLX) filed a Form 144 disclosing a proposed sale of 138,358 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $9,266,548.29. The filing shows the shares are outstanding among a total of 222,419,282 shares and names NASDAQ as the exchange with an approximate sale date of 09/22/2025. The acquisition row lists an option grant dated 11/05/2015 and a recorded acquisition date of 09/22/2025, and payment is noted as cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is unaware of undisclosed material adverse information.
Hologic, Inc. filed a current report noting a change to its top leadership contract. On September 18, 2025, the company and Stephen P. MacMillan, its Chairman, President and Chief Executive Officer, amended his employment agreement. The amendment solely extends the term of his existing amended and restated agreement dated September 18, 2015, as amended, so that it continues in effect until it is otherwise terminated by either the company or Mr. MacMillan in accordance with its terms. This update maintains continuity in Hologic’s leadership structure without describing any other changes to his role or compensation.
Hologic (HOLX) Q3 FY25 10-Q highlights: Revenue edged up 1.2% YoY to $1.024 bn, with U.S. sales flat and Europe +16% offsetting a 7% decline in Asia-Pac. Diagnostics grew 2% to $449 m and GYN Surgical +7% to $178 m, while Breast Health fell 5% to $365 m. Gross margin improved 100 bp to 56.4%, lifting operating income 4% to $254.6 m. Net income was stable at $194.9 m; diluted EPS rose 5% to $0.86 on a 5% lower share count.
Year-to-date revenue was flat at $3.05 bn, but $221 m of intangible impairments pushed net income down 38% to $378.5 m (EPS $1.66). Operating cash flow fell 24% to $702 m, while the company spent $753 m on share buybacks and $322 m on acquisitions, cutting cash to $1.74 bn (-$425 m since Sept-24). Debt remains ~ $2.5 bn; on 15 Jul 25 HOLX refinanced its credit facility, trimming the term loan to $1.17 bn and keeping a $1.25 bn revolver.
Balance-sheet leverage is modest (net cash > $-0.4 bn) and equity totals $4.84 bn. Remaining performance obligations stand at $898 m, 58% due within three years. Management continues portfolio pruning (SSI divestiture) and expansion (Gynesonics $341 m, Endomag $314 m) while absorbing restructuring costs ($17.6 m YTD).
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
